Skip to main content

NPF Releases Guidance for the New COVID-19 Vaccine

The National Psoriasis Foundation (NPF) COVID-19 Task Force updated their guidance statements to include recommendations for the new vaccine against SARS-CoV-2. The new recommendations include:

  • Patients with psoriatic disease and no contraindications to the vaccine should be vaccinated as soon as it becomes available to them at the federal, state, and local levels. If supply is limited, Centers for Disease Control and Prevention (CDC) recommendations for prioritizing early vaccination in selected groups should be followed based on comorbidities and work setting.
  • Patients who receive the COVID-19 vaccine should continue their biologic or oral therapies for psoriasis and psoriatic arthritis. Systemic medications for psoriatic disease are not contraindications for the vaccine.
  • For patients deciding whether to participate in a clinical trial for a therapy or vaccine against COVID-19, the task force recommends making this decision on a case-by-case basis and with shared decision-making between the patient, provider, and researcher.

The CDC released a statement regarding COVID-19 vaccine recommendations while supplies are limited. The special groups to be vaccinated first include health care works and persons living in long-term care facilities. Visit the CDC for more information regarding the vaccine.

Visit the NPF for a complete list of recommendations from the NPF COVID-19 Tack Force.

Watch Dr Joel Gelfand discuss approaches to psoriasis treatment based on the American Academy of Dermatology and NPF guidance statements.


COVID-19 Task Force Guidance Statements. National Psoriasis Foundation. Updated December 12, 2020. Accessed December 15, 2020.

Back to Top